Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer

<p>Supplementary Figure 16. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition monotherapy among patients with advanced/metastatic NSCLC, according to ATM/TP53 co-mutation status. (D) Objective response rate, (E) progression-free survival...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Biagio Ricciuti (14951247) (author)
Diğer Yazarlar:	Arielle Elkrief (15055750) (author), Joao Alessi (15561455) (author), Xinan Wang (15561458) (author), Yvonne Li (15561461) (author), Hersh Gupta (15561464) (author), Daniel M. Muldoon (15561467) (author), Arrien A. Bertram (14954848) (author), Federica Pecci (15561470) (author), Giuseppe Lamberti (15024714) (author), Alessandro Di Federico (15561473) (author), Adriana Barrichello (15561476) (author), Victor R. Vaz (15561479) (author), Malini Gandhi (15561482) (author), Elinton Lee (15561485) (author), Geoffrey I. Shapiro (14961801) (author), Hyesun Park (15561488) (author), Mizuki Nishino (15561491) (author), James Lindsay (15032271) (author), Kristen D. Felt (15561494) (author), Bijaya Sharma (15561497) (author), Andrew D. Cherniack (14959412) (author), Scott Rodig (15561500) (author), Daniel R. Gomez (15561503) (author), Narek Shaverdian (15561506) (author), Mehrdad Rakaee (15561509) (author), Chaitanya Bandlamudi (15047205) (author), Marc Ladanyi (15050661) (author), Pasi A. Janne (15561512) (author), Adam J. Schoenfeld (15022025) (author), Lynette M. Sholl (15032729) (author), Mark M. Awad (14961722) (author), Michael L. Cheng (15561515) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Genetic biomarkers DNA Damage and Repair DNA repair Lung Cancer Precision Medicine Translational Research
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

_version_	1849927632022405120
author	Biagio Ricciuti (14951247)
author2	Arielle Elkrief (15055750) Joao Alessi (15561455) Xinan Wang (15561458) Yvonne Li (15561461) Hersh Gupta (15561464) Daniel M. Muldoon (15561467) Arrien A. Bertram (14954848) Federica Pecci (15561470) Giuseppe Lamberti (15024714) Alessandro Di Federico (15561473) Adriana Barrichello (15561476) Victor R. Vaz (15561479) Malini Gandhi (15561482) Elinton Lee (15561485) Geoffrey I. Shapiro (14961801) Hyesun Park (15561488) Mizuki Nishino (15561491) James Lindsay (15032271) Kristen D. Felt (15561494) Bijaya Sharma (15561497) Andrew D. Cherniack (14959412) Scott Rodig (15561500) Daniel R. Gomez (15561503) Narek Shaverdian (15561506) Mehrdad Rakaee (15561509) Chaitanya Bandlamudi (15047205) Marc Ladanyi (15050661) Pasi A. Janne (15561512) Adam J. Schoenfeld (15022025) Lynette M. Sholl (15032729) Mark M. Awad (14961722) Michael L. Cheng (15561515)
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
author_facet	Biagio Ricciuti (14951247) Arielle Elkrief (15055750) Joao Alessi (15561455) Xinan Wang (15561458) Yvonne Li (15561461) Hersh Gupta (15561464) Daniel M. Muldoon (15561467) Arrien A. Bertram (14954848) Federica Pecci (15561470) Giuseppe Lamberti (15024714) Alessandro Di Federico (15561473) Adriana Barrichello (15561476) Victor R. Vaz (15561479) Malini Gandhi (15561482) Elinton Lee (15561485) Geoffrey I. Shapiro (14961801) Hyesun Park (15561488) Mizuki Nishino (15561491) James Lindsay (15032271) Kristen D. Felt (15561494) Bijaya Sharma (15561497) Andrew D. Cherniack (14959412) Scott Rodig (15561500) Daniel R. Gomez (15561503) Narek Shaverdian (15561506) Mehrdad Rakaee (15561509) Chaitanya Bandlamudi (15047205) Marc Ladanyi (15050661) Pasi A. Janne (15561512) Adam J. Schoenfeld (15022025) Lynette M. Sholl (15032729) Mark M. Awad (14961722) Michael L. Cheng (15561515)
author_role	author
dc.creator.none.fl_str_mv	Biagio Ricciuti (14951247) Arielle Elkrief (15055750) Joao Alessi (15561455) Xinan Wang (15561458) Yvonne Li (15561461) Hersh Gupta (15561464) Daniel M. Muldoon (15561467) Arrien A. Bertram (14954848) Federica Pecci (15561470) Giuseppe Lamberti (15024714) Alessandro Di Federico (15561473) Adriana Barrichello (15561476) Victor R. Vaz (15561479) Malini Gandhi (15561482) Elinton Lee (15561485) Geoffrey I. Shapiro (14961801) Hyesun Park (15561488) Mizuki Nishino (15561491) James Lindsay (15032271) Kristen D. Felt (15561494) Bijaya Sharma (15561497) Andrew D. Cherniack (14959412) Scott Rodig (15561500) Daniel R. Gomez (15561503) Narek Shaverdian (15561506) Mehrdad Rakaee (15561509) Chaitanya Bandlamudi (15047205) Marc Ladanyi (15050661) Pasi A. Janne (15561512) Adam J. Schoenfeld (15022025) Lynette M. Sholl (15032729) Mark M. Awad (14961722) Michael L. Cheng (15561515)
dc.date.none.fl_str_mv	2025-11-25T13:29:00Z
dc.identifier.none.fl_str_mv	10.1158/1078-0432.30709330
dc.relation.none.fl_str_mv	https://figshare.com/articles/figure/Supplementary_Figure_16_from_Clinicopathologic_Genomic_and_Immunophenotypic_Landscape_of_i_ATM_i_Mutations_in_Non_Small_Cell_Lung_Cancer/30709330
dc.rights.none.fl_str_mv	CC BY info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv	Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Genetic biomarkers DNA Damage and Repair DNA repair Lung Cancer Precision Medicine Translational Research
dc.title.none.fl_str_mv	Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
dc.type.none.fl_str_mv	Image Figure info:eu-repo/semantics/publishedVersion image
description	<p>Supplementary Figure 16. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition monotherapy among patients with advanced/metastatic NSCLC, according to ATM/TP53 co-mutation status. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 inhibition in combination with chemotherapy among patients with advanced NSCLC, according to ATM/TP53 co-mutation status.</p>
eu_rights_str_mv	openAccess
id	Manara_35cfd74609b7de1e4fcbd9a279a28eaf
identifier_str_mv	10.1158/1078-0432.30709330
network_acronym_str	Manara
network_name_str	ManaraRepo
oai_identifier_str	oai:figshare.com:article/30709330
publishDate	2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv	CC BY
spelling	Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung CancerBiagio Ricciuti (14951247)Arielle Elkrief (15055750)Joao Alessi (15561455)Xinan Wang (15561458)Yvonne Li (15561461)Hersh Gupta (15561464)Daniel M. Muldoon (15561467)Arrien A. Bertram (14954848)Federica Pecci (15561470)Giuseppe Lamberti (15024714)Alessandro Di Federico (15561473)Adriana Barrichello (15561476)Victor R. Vaz (15561479)Malini Gandhi (15561482)Elinton Lee (15561485)Geoffrey I. Shapiro (14961801)Hyesun Park (15561488)Mizuki Nishino (15561491)James Lindsay (15032271)Kristen D. Felt (15561494)Bijaya Sharma (15561497)Andrew D. Cherniack (14959412)Scott Rodig (15561500)Daniel R. Gomez (15561503)Narek Shaverdian (15561506)Mehrdad Rakaee (15561509)Chaitanya Bandlamudi (15047205)Marc Ladanyi (15050661)Pasi A. Janne (15561512)Adam J. Schoenfeld (15022025)Lynette M. Sholl (15032729)Mark M. Awad (14961722)Michael L. Cheng (15561515)CancerMolecular and Cellular BiologyCancer Detection and DiagnosisTherapeutic Research and DevelopmentClinical Research and TrialsBiomarkersGenetic biomarkersDNA Damage and RepairDNA repairLung CancerPrecision MedicineTranslational Research<p>Supplementary Figure 16. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition monotherapy among patients with advanced/metastatic NSCLC, according to ATM/TP53 co-mutation status. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 inhibition in combination with chemotherapy among patients with advanced NSCLC, according to ATM/TP53 co-mutation status.</p>2025-11-25T13:29:00ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30709330https://figshare.com/articles/figure/Supplementary_Figure_16_from_Clinicopathologic_Genomic_and_Immunophenotypic_Landscape_of_i_ATM_i_Mutations_in_Non_Small_Cell_Lung_Cancer/30709330CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307093302025-11-25T13:29:00Z
spellingShingle	Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Biagio Ricciuti (14951247) Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Genetic biomarkers DNA Damage and Repair DNA repair Lung Cancer Precision Medicine Translational Research
status_str	publishedVersion
title	Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
title_full	Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
title_fullStr	Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
title_full_unstemmed	Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
title_short	Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
title_sort	Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
topic	Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Genetic biomarkers DNA Damage and Repair DNA repair Lung Cancer Precision Medicine Translational Research

Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer

Benzer Materyaller